The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Complete Remissions in Hairy Cell Leukemia with 2-Chlorodeoxyadenosine after Failure with 2-Deoxycoformycin

Alan Saven; and Lawrence D. Piro
[+] Article, Author, and Disclosure Information

From the Scripps Clinic and Research Foundation, La Jolla, California. Requests for Reprints: Alan Saven, MD, Scripps Clinic and Research Foundation, 10666 North Torrey Pines Road, La Jolla, CA 92037. Acknowledgments: The authors thank Mary-Helen Hader for data collection; Melba Nelson, RN, for nursing assistance; and the nursing staff of the General Clinical Research Center for their assistance.

Copyright 2004 by the American College of Physicians

Ann Intern Med. 1993;119(4):278-283. doi:10.7326/0003-4819-119-4-199308150-00005
Text Size: A A A

Objective: To determine whether clinical cross-resistance and intolerance exists between the nucleosides 2-deoxycoformycin (DCF) and 2-chlorodeoxyadenosine (2-CdA) in the treatment of patients with hairy cell leukemia despite similar structures and mechanisms of action.

Design: Phase II clinical study.

Setting: Referral cancer center.

Participants: Five patients with hairy cell leukemia who had been previously treated with DCF.

Intervention: Single course of 2-CdA at 0.1 mg/kg body weight per day for 7 days by continuous intravenous infusion.

Results: Of five patients, three were resistant to and two were intolerant of (having had life-threatening toxic reactions) DCF therapy. Four patients obtained a complete response with a median follow-up period of more than 11 months. The other patient in whom splenectomy, interferon, and DCF treatments were unsuccessful had a partial response lasting 2 months and subsequently died of Streptococcus pneumoniae bacteremia. Three of the four patients with complete responses remain in unmaintained remission, whereas the fourth has progressive splenic enlargement with stable hematologic parameters. The median leukocyte count increased from 2.0 109/L to 3.8 109/L, the median absolute neutrophil count increased from 0.56 109/L to 2.73 109/L, the median hemoglobin level increased from 112 g/L to 140 g/L, and the median platelet count increased from 55 109/L to 123 109/L. Two patients had culture-negative neutropenic fever associated with treatment.

Conclusions: 2-Chlorodeoxyadenosine induced complete responses in patients with hairy cell leukemia resistant to DCF, suggesting a lack of cross-resistance. Also, 2-CdA is not prohibitively toxic in patients intolerant of DCF.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Journal Club
Topic Collections
PubMed Articles
Long-term follow-up after purine analogue therapy in hairy cell leukaemia. Best Pract Res Clin Haematol 2015;28(4):217-29.
Chemoimmunotherapy for hairy cell leukemia. Best Pract Res Clin Haematol 2015;28(4):230-5.
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.